Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
about
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyPharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.Erlotinib and pantoprazole: a relevant interaction or not?Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsChemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinibShould the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents.Therapeutic drug monitoring in cancer chemotherapy.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.Drug-drug interactions in patients receiving tyrosine kinase inhibitors.Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.Spectroscopic studies on the interaction between erlotinib hydrochloride and bovine serum albumin.Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma.Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Interaction between fasudil hydrochloride and bovine serum albumin: spectroscopic study.Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
P2860
Q28482219-65BF82DF-ECC0-42FA-8428-B7306D8041FEQ33551899-8605F650-4638-4362-9AAF-CC7BA945BC5BQ34266864-227A6D90-6C5B-4754-9500-E62D0F97AA09Q34457467-6CFD6318-008D-4DAB-B9F6-5E52BD7AC383Q34480582-32F52E68-CAE1-45AC-8879-5EA15EC24B71Q35154257-4BD8B7ED-A397-4DBC-AFCE-53A3C36E7671Q35708124-EFBAA095-7C7D-4E27-B17A-4D877793C276Q35749286-8D60A950-5C88-4304-887C-19A49FDF3663Q35992745-7FCCE154-2FEC-43D6-85F3-EE3AF14DD9B5Q37728849-F27DFF18-09C1-46E0-8052-73EA19973443Q37780614-EE80B23D-F860-4150-AF2A-D636F638D087Q37810220-592803A9-7691-4B8A-8564-F6FE68B75ADBQ38190857-52BD8DC5-D9DB-437B-8433-77DF46F57FAEQ38207943-F1AF8BF4-127B-4968-8A81-131417DAD00DQ38243832-75290C69-4D3B-4F0B-9EA5-E02C23665C4AQ38379295-B0CF921C-0505-4AB9-9E7F-6875559BA4A5Q38818845-6A39A126-712D-4754-9C15-051187C4CFB3Q39048761-1F6969F6-BBEF-4D2D-BB25-5B6BD0734B9DQ39111080-3ECF0452-92F0-46B4-B035-CF4C5140BCC9Q39321056-7D96A8C1-A18B-4EDA-BB27-E41C875089FFQ39651800-1B9E691C-63F5-4CE6-A178-D2268C605001Q41880312-A501310F-963D-4A73-9A83-D12FAECFEC8AQ43515674-376CA725-19CA-4609-93DB-D22F33E021FFQ44185661-F1189AC4-7BBE-4918-AFA7-28B4FFE4C0E6Q45662172-A0529371-F444-4D3C-B8E4-94323BC94A82Q47969048-5C08160E-9855-4F25-A709-8F0A477189D4Q51651088-6BCB4348-2140-4965-9F96-1355A35BFA34Q54520157-572CA6E5-CAE6-432E-9EB3-2CBEB8D0E241Q54557871-284F269E-F9B2-43B0-8160-A72D518BA11D
P2860
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Population pharmacokinetics of ...... neck squamous cell carcinoma.
@en
Population pharmacokinetics of ...... neck squamous cell carcinoma.
@nl
type
label
Population pharmacokinetics of ...... neck squamous cell carcinoma.
@en
Population pharmacokinetics of ...... neck squamous cell carcinoma.
@nl
prefLabel
Population pharmacokinetics of ...... neck squamous cell carcinoma.
@en
Population pharmacokinetics of ...... neck squamous cell carcinoma.
@nl
P2093
P50
P1476
Population pharmacokinetics of ...... d neck squamous cell carcinoma
@en
P2093
Adil Benlyazid
Isabelle Hennebelle
Jean Pierre Delord
Jean-Louis Lefebvre
Jérôme Sarini
Laurence Malard
P304
P356
10.1016/J.EJCA.2009.05.007
P577
2009-06-10T00:00:00Z